It is used in the treatment of heart failure in combination with valsartan [54], and was also the first dual inhibitor of AT1 receptors for angiotensin II and neutral endopeptidase (NEP) to be used by the FDA, in 2015 [55]. The gene discussed is MME; the disease is heart failure.